Contract Research Organization (CRO) Market - By Segment (Drug Discovery, Clinical Development), By Clinical Trial Phase (Preclinical Trials, Phase I, Phase II, Phase III), By End Users (Pharmaceutical Companies) - Forecast 2027
|ID: VPR/HC/1002||Publishing Year: September 2021||Pages: 197||Format:|
Contract Research Organization (CRO) Market Overview:
The Contract Research Organization (CRO) Market valued at USD 40 Million in 2020 and is expected to reach USD 68 Million by 2027, registering a CAGR of 7.8% from 2020 to 2027.
In recent years, CRO services have increasingly gained traction in the healthcare industry. CROs are gaining traction in the healthcare sector, thanks to major advancements in research, drugs, and drug delivery, among other things. The demand for CRO services is likely to expand at a high rate during the forecast period as healthcare providers continue to recognise the benefits and advantages of consulting and choosing for CRO services (2019-2027). Instead of outsourcing the entire project, biotech companies have been moving toward outsourcing parts of clinical trials to CROs in recent years. Furthermore, participants in the current Contract Research Organization (CRO) Market are concentrating their efforts on meeting the unique and specific needs of clinical trials.
In recent years, CRO services have aided corporations in the early stages of drug and pharmaceutical development. Pharmaceutical firms are increasingly using clinical research, consultancy, and laboratory CRO services, which is projected to drive the Contract Research Organization (CRO) Market during the forecast period. Furthermore, stakeholders in the existing contract research organisation (CRO) services market are expected to work together to develop open technology standards that would likely change clinical trial operations in the future.
- IQVIA Inc.
- Syneos Health, Inc.
- Parexel International Corporation
- PRA Health Sciences, Inc.
- PPD, Inc.
- Charles River Laboratories, Inc.
- Icon plc
- WuXiAppTec Group
COVID-19's recent outbreak has had a beneficial or negative impact on a variety of healthcare businesses. This pandemic has had a significant negative impact on the CRO industry's growth. Investors' focus shifted from non-COVID-19 pharmaceuticals and medical devices to COVID-19 diagnosis and therapy in 2019-2020, disrupting planned and ongoing R&D and clinical trials.
Clinical trials were 1,210 in June 2020, down to 1,180 in August 2020, according to the Clinical Trials Online Magazine. The suspension of enrolments, the lengthy enrolment process, delayed initializations, and a changed focus confined to COVID-19 studies are all contributing to the decrease in the number of clinical trials and disruptions in studies.
The pharmaceutical industry has seen a significant growth in research and development over the last decade. Established pharmaceutical companies are moving toward smaller business models with a high reliance on external entities such as CROs. The biotech industry's rapid expansion over the last decade has resulted in an increase in the number of businesses engaged in research and medication development. The exponential growth in the number of active and forthcoming drug development businesses and research projects has generated a tremendous window of opportunity for Contract Research Organisation(CRO) Services Industry stakeholders. Over the last decade, outsourcing significant or difficult elements of the drug development process has become essential for the effective and cost-effective development of new medications.
Despite the fact that drug researchers are increasingly using CRO services, they are still looking for ways to handle a number of issues that come with this method, such as expensive R&D costs, gaining access to and tracking outsourced activities, and capacity limits, to name a few. At this time, stakeholders in the contract research organisation (CRO) services industry are expected to handle contracted work in a variety of ways in order to react to changing research and development requirements. In the recent decade, the number of outsourced projects has changed the general structure of the drug development sector.
The Contract Research Organization (CRO) Market is divided into Segments, Clinical Trial Phases, and End Users.
The Contract Research Organization (CRO) Market is divided into segments such as drug discovery, clinical development, post-market services, and others.
The Contract Research Organization (CRO) Market is divided into preclinical trials, phase I, phase II, phase III, phase IV, and others based on clinical trials.
The Contract Research Organization (CRO) Market is divided into pharmaceutical/biotechnology firms, medical device businesses, academic institutes, and others based on end users.
Because of its well-developed healthcare industry and large patient population, the Americas lead the Contract Research Organization (CRO) Market Aside from that, changing lifestyles and rising healthcare costs have aided the market's expansion in the United States. Furthermore, the presence of major economies such as the United States and Canada in the region would help to drive market growth.
Europe is the world's second-largest Contract Research Organization (CRO) Market, trailing Asia Pacific. During the forecasted period, the availability of money for research, a large patient population, rising healthcare expenditures, a well-developed healthcare sector, and government support for research and development are expected to fuel market growth. Europe is separated into two regions: Western Europe and Eastern Europe. Western Europe controls the majority of the regional market, with Germany, the United Kingdom, and France playing key roles. Eastern Europe, on the other hand, is the fastest-growing region due to the vast unexplored market prospects.
Type Here for table of content.